Scleroderma: a treatable disease.

Abstract

Many effective treatments for scleroderma have emerged in recent years, including bosentan, an endothelin receptor antagonist, and epoprostenol, a prostacyclin, both of which target vasoconstriction. Cyclophosphamide may soon be proven effective against interstitial lung disease.

• Authors: Joseph H Korn
• Journal: Cleveland Clinic journal of medicine (Cleve Clin J Med) Vol. 70 Issue 11 Pg. 954, 956, 958 passim (Nov 2003) ISSN: 0891-1150 [Print] United States
• PMID: 14650470 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Angiotensin-Converting Enzyme Inhibitors
• Antihypertensive Agents
• Sulfonamides
• Bosentan

Topics

• Angiotensin-Converting Enzyme Inhibitors (therapeutic use)
• Antihypertensive Agents (therapeutic use)
• Bosentan
• Humans
• Pulmonary Fibrosis (etiology)
• Scleroderma, Systemic (complications, physiopathology, therapy)
• Sulfonamides (therapeutic use)